logo

Seattle Genetics Inc. (SGEN)



Trade SGEN now with
  Date
  Headline
5/17/2018 9:05:59 AM Seattle Genetics Appoints Roger Dansey As Chief Medical Officer
4/26/2018 4:05:00 PM Seattle Genetics Q1 Loss/share $0.73 Vs. Loss $0.42 Year Ago
4/12/2018 8:05:19 AM Seattle Genetics Highlights Novel Antibody-Drug Conjugate Technologies And Immuno-Oncology Program Advances At AACR
3/26/2018 8:03:16 AM Astellas, Seattle Genetics Receive FDA Breakthrough Therapy Designation For Enfortumab Vedotin
3/26/2018 8:02:01 AM Seattle Genetics And Astellas Receive FDA Breakthrough Therapy Designation For Enfortumab Vedotin
3/15/2018 8:00:37 AM Seattle Genetics Appoints Alpna Seth To Board
3/9/2018 9:27:34 AM Seattle Genetics Closes Acquisition Of Cascadian Therapeutics
3/9/2018 6:00:40 AM Seattle Genetics Completes Tender Offer For All Shares Of Cascadian Therapeutics
3/7/2018 8:02:06 AM Seattle Genetics Begins New Phase 1 Study In Relapsed Or Refractory Multiple Myeloma
2/16/2018 8:02:42 AM Seattle Genetics Gets US Regulatory Approval For Proposed Acquisition Of Cascadian Therapeutics
2/9/2018 6:45:57 AM Seattle Genetics And Pieris Pharma Announce Multi-Program Immuno-Oncology Collaboration
2/8/2018 5:40:05 PM Seattle Genetics Begins Tender Offer For Cascadian Therapeutics
2/6/2018 4:04:40 PM Seattle Genetics Q4 Loss Per Share $0.41 Vs Loss $0.39 Last Year